Argent Capital Management Holds Holding in Conocophillips (COP); As Gilead Sciences (GILD) Market Value Declined, Holder Steinberg Global Asset Management Has Increased Its Position

June 13, 2018 - By Marie Mckinney

Gilead Sciences, Inc. (NASDAQ:GILD) Logo

Steinberg Global Asset Management increased its stake in Gilead Sciences Inc (GILD) by 288.06% based on its latest 2018Q1 regulatory filing with the SEC. Steinberg Global Asset Management bought 36,448 shares as the company’s stock declined 17.62% with the market. The institutional investor held 49,101 shares of the health care company at the end of 2018Q1, valued at $3.70M, up from 12,653 at the end of the previous reported quarter. Steinberg Global Asset Management who had been investing in Gilead Sciences Inc for a number of months, seems to be bullish on the $93.35B market cap company. The stock increased 0.16% or $0.115 during the last trading session, reaching $71.795. About 1.25M shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has risen 4.37% since June 13, 2017 and is uptrending. It has underperformed by 8.20% the S&P500. Some Historical GILD News: 15/05/2018 – Geode Capital Adds Valeant, Exits pSivida, Buys More Gilead; 05/03/2018 – Gilead Sciences: Women in Biktarvy Treatment Arm Maintained High Rates of Virologic Suppression; 05/03/2018 – Gilead Sciences: No Patients in Biktarvy Treatment Arm Demonstrated Treatment-Emergent Resistance Through 48 Weeks; 31/05/2018 – ACR20 80 — not too shabby: Gilead and Galapagos bag promising PhII data for star immunology drug filgotinib – boosting late-stage focus $GILD $GLPG; 30/05/2018 – GILEAD, GALAPAGOS: EQUATOR ACHIEVES PRIMARY ENDPOINT OF ACR20; 21/03/2018 – STAT Plus: Gilead patent for its Sovaldi hepatitis C drug is rejected in Ukraine; 30/05/2018 – GALAPAGOS NV – FILGOTINIB WAS GENERALLY WELL-TOLERATED IN EQUATOR TRIAL, WITH NO NEW SAFETY SIGNALS OBSERVED; 30/04/2018 – Gilead’s Descovy Falls For 2nd Wk, Odefsey Declines: HIV; 15/05/2018 – U.S. Food and Drug Administration Approves Expanded lndication for Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents; 23/04/2018 – Gilead’s Descovy Falls After 2-Wk Rise, Triumeq Declines: HIV

Argent Capital Management Llc increased its stake in Conocophillips (COP) by 211.74% based on its latest 2018Q1 regulatory filing with the SEC. Argent Capital Management Llc bought 840,295 shares as the company’s stock rose 15.69% while stock markets declined. The institutional investor held 1.24M shares of the integrated oil company at the end of 2018Q1, valued at $73.35M, up from 396,852 at the end of the previous reported quarter. Argent Capital Management Llc who had been investing in Conocophillips for a number of months, seems to be bullish on the $80.82B market cap company. The stock decreased 0.52% or $0.36 during the last trading session, reaching $69.07. About 1.78M shares traded. ConocoPhillips (NYSE:COP) has risen 45.33% since June 13, 2017 and is uptrending. It has outperformed by 32.76% the S&P500. Some Historical COP News: 26/04/2018 – CONOCOPHILLIPS – ON TRACK FOR FULL-YEAR SHARE REPURCHASES OF $2 BLN; 17/04/2018 – Malaysia’s Kimanis crude supplies to drop in June -traders; 11/04/2018 – ConocoPhillips to cut 450 UK jobs on Southern North Sea production halt; 29/03/2018 – Business Journals: Exclusive: Oxy ‘evaluating’ plan to buy former ConocoPhillips campus; 16/05/2018 – U.S. STATE DEPT REMAINS IN CLOSE CONTACT WITH CARIBBEAN PARTNERS TO REDUCE RISK OF OIL SUPPLY DISRUPTIONS – SPOKESMAN; 16/03/2018 – EIN ConocoPhillips: Cenovus seeks partner for C$1.3 bln Narrows Lake project; 11/05/2018 – PDVSA moves to protect exports as Conoco seizures weigh; 06/03/2018 – EAST TIMOR TO RECEIVE 70 PCT OF GREATER SUNRISE REVENUE IF GAS PIPED ONSHORE OR 80 PCT IF PIPED TO AUSTRALIA; 26/04/2018 – ConocoPhillips ups output forecast for 2018; 26/04/2018 – ConocoPhillips 1Q Adj EPS 96c

More notable recent ConocoPhillips (NYSE:COP) news were published by: 247Wallst.com which released: “Short Sellers Run For Cover From Major Oil Stocks” on June 12, 2018, also Benzinga.com with their article: “A Pair Trade In E&P: Bernstein Upgrades ConocoPhillips, Downgrades Concho” published on June 08, 2018, Benzinga.com published: “BMO Offers 11 Reasons To Like ConocoPhillips” on June 11, 2018. More interesting news about ConocoPhillips (NYSE:COP) were released by: Fool.com and their article: “ConocoPhillips and Chevron Stock Win Analysts’ Favor: What You Need to Know” published on June 11, 2018 as well as Globenewswire.com‘s news article titled: “Report: Developing Opportunities within ConocoPhillips, Teleflex, Enterprise Products Partners, Tandem Diabetes …” with publication date: June 12, 2018.

Argent Capital Management Llc, which manages about $2.51 billion and $2.73B US Long portfolio, decreased its stake in Carbonite Inc. (NASDAQ:CARB) by 137,845 shares to 131,540 shares, valued at $3.79 million in 2018Q1, according to the filing. It also reduced its holding in Pfizer Inc. (NYSE:PFE) by 15,109 shares in the quarter, leaving it with 615,236 shares, and cut its stake in Johnson & Johnson (NYSE:JNJ).

Among 28 analysts covering ConocoPhillips (NYSE:COP), 17 have Buy rating, 1 Sell and 10 Hold. Therefore 61% are positive. ConocoPhillips had 104 analyst reports since August 4, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Sunday, August 20 by Cowen & Co. The firm earned “Outperform” rating on Friday, February 5 by RBC Capital Markets. The firm earned “Buy” rating on Tuesday, October 20 by Bank of America. The firm earned “Outperform” rating on Friday, August 7 by Bernstein. The stock of ConocoPhillips (NYSE:COP) earned “Buy” rating by Goldman Sachs on Monday, November 28. Scotia Capital maintained the shares of COP in report on Friday, April 7 with “Buy” rating. The firm has “Outperform” rating given on Friday, February 5 by Bernstein. The firm has “Buy” rating by Cowen & Co given on Wednesday, September 27. On Tuesday, August 29 the stock rating was maintained by Jefferies with “Buy”. Piper Jaffray maintained the stock with “Buy” rating in Tuesday, January 23 report.

Investors sentiment decreased to 0.67 in 2018 Q1. Its down 0.05, from 0.72 in 2017Q4. It dived, as 51 investors sold COP shares while 555 reduced holdings. 101 funds opened positions while 302 raised stakes. 805.59 million shares or 0.00% less from 805.62 million shares in 2017Q4 were reported. Cypress Capital Gp holds 0.37% in ConocoPhillips (NYSE:COP) or 29,890 shares. Tide Point Cap Mgmt Ltd Partnership stated it has 968,144 shares. Canandaigua Savings Bank Trust holds 30,190 shares. Old Mutual Customised Solutions (Proprietary) owns 86,826 shares. Farmers State Bank accumulated 3,506 shares. 195,036 are owned by Flippin Bruce Porter. Los Angeles Capital Mngmt & Equity Research Inc reported 0.18% in ConocoPhillips (NYSE:COP). 10,532 are held by Koch. Clearbridge Invs Ltd Liability Corp, New York-based fund reported 9,072 shares. Family Firm Inc has 4,308 shares. Ingalls & Snyder Limited Liability Company, a New York-based fund reported 65,215 shares. Piedmont Inv Advsrs Ltd Liability has 177,351 shares for 0.28% of their portfolio. Capwealth Advsr Limited Liability accumulated 6,540 shares. Keating Counselors Incorporated stated it has 0.31% of its portfolio in ConocoPhillips (NYSE:COP). Ntv Asset Management Limited Liability Corp holds 0.27% in ConocoPhillips (NYSE:COP) or 16,244 shares.

Since March 29, 2018, it had 0 insider purchases, and 8 selling transactions for $20.96 million activity. Schwarz Glenda Mae also sold $439,862 worth of ConocoPhillips (NYSE:COP) on Friday, May 25. Another trade for 25,000 shares valued at $1.47 million was made by LUNDQUIST ANDREW D on Thursday, March 29. 3,716 shares valued at $243,586 were sold by Freeman Jody on Monday, April 30.

Since January 2, 2018, it had 0 buys, and 23 selling transactions for $48.21 million activity. Shares for $4.68 million were sold by WILSON GAYLE E. Washington Robin L had sold 5,000 shares worth $401,566 on Wednesday, February 21. MARTIN JOHN C also sold $3.66 million worth of Gilead Sciences, Inc. (NASDAQ:GILD) on Monday, April 2. The insider Alton Gregg H sold $1.97M. Meyers James R had sold 100,000 shares worth $8.02M.

Among 31 analysts covering Gilead Sciences (NASDAQ:GILD), 22 have Buy rating, 0 Sell and 9 Hold. Therefore 71% are positive. Gilead Sciences had 132 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was upgraded by Jefferies to “Buy” on Tuesday, September 6. The firm earned “Equal-Weight” rating on Friday, October 6 by Morgan Stanley. The firm earned “Hold” rating on Tuesday, July 26 by Needham. Wells Fargo maintained the shares of GILD in report on Friday, December 4 with “Market Perform” rating. Morgan Stanley maintained Gilead Sciences, Inc. (NASDAQ:GILD) rating on Thursday, May 26. Morgan Stanley has “Equal-Weight” rating and $103 target. The rating was maintained by Cowen & Co on Tuesday, May 30 with “Buy”. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Neutral” rating given on Wednesday, February 8 by Citigroup. The rating was maintained by UBS on Friday, April 29 with “Buy”. The rating was maintained by Jefferies on Wednesday, August 31 with “Hold”. Credit Suisse maintained the shares of GILD in report on Wednesday, January 3 with “Hold” rating.

Steinberg Global Asset Management, which manages about $604.10 million and $678.24 million US Long portfolio, decreased its stake in Cerner Corp (NASDAQ:CERN) by 6,157 shares to 16,379 shares, valued at $950,000 in 2018Q1, according to the filing. It also reduced its holding in Abbvie Inc (NYSE:ABBV) by 12,880 shares in the quarter, leaving it with 67,638 shares, and cut its stake in Ishares Tr (PFF).

More notable recent Gilead Sciences, Inc. (NASDAQ:GILD) news were published by: Seekingalpha.com which released: “Gilead’s Evolution In Oncology, With Comments On Valuation” on June 07, 2018, also 247Wallst.com with their article: “Short Sellers Up the Ante For Major Biotechs” published on June 12, 2018, Nasdaq.com published: “5 Top Stocks to Buy in June” on June 01, 2018. More interesting news about Gilead Sciences, Inc. (NASDAQ:GILD) were released by: Seekingalpha.com and their article: “The Kite Killer – TapImmune And Marker Merger Challenges Gilead” published on May 30, 2018 as well as Bizjournals.com‘s news article titled: “Gilead, BioMarin among Bay Area drug makers shamed by FDA in generics ‘gaming’ list” with publication date: May 17, 2018.

ConocoPhillips (NYSE:COP) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts